<DOC>
	<DOCNO>NCT00715884</DOCNO>
	<brief_summary>The objective study show similar ( non-inferior ) safety effectiveness CYPHER® ELITE™ CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems prospective , multi-center , randomized clinical study treatment de novo native coronary lesion .</brief_summary>
	<brief_title>Study Comparing CYPHER® ELITE™ CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems</brief_title>
	<detailed_description>A prospective , single-blind , randomize , multicenter , two arm study . The objective study show similar ( non-inferior ) safety effectiveness CYPHER® ELITE™ CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems prospective , multi-center , randomized clinical study treatment de novo native coronary lesion .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects de novo atherosclerotic CAD 1 2 vessel ; The subject must &gt; /= 18 year age ; Female childbearing potential must negative pregnancy test within 7 day prior enrollment ; Diagnosis angina pectoris define stable angina pectoris Canadian Cardiovascular Society Classification ( Class I , II , III ) OR nonST segment elevation acute coronary syndrome ( Braunwald Classification B &amp; C ) OR nonST segment elevation myocardial infarction &gt; /= 48 hour time study index procedure OR asymptomatic subject positive stress test ; Treatment &lt; /= two lesion one two major coronary artery ( 1 target lesion 2 vessel 2 target lesion 1 vessel ) ; Target vessel diameter must &gt; /= 2.25mm &lt; /= 4.0 diameter ( visual estimate ) ; Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) ; Target lesion length &lt; 30mm ( target lesion ( ) ) total implanted stent length &lt; 66mm . Additional stent use treat dissection , etc , : however , must stent subject randomize study . Subject Legally Authorized Representative must provide write informed consent prior procedure use form approve Institutional Review Board/Independent Ethics Committee . ST Segment Elevation Myocardial Infarction ( STEMI ) within 30 day study index procedure ; Unprotected leave main coronary disease &gt; /= 50 % stenosis ; Total coronary occlusion TIMI grade 0 1 target vessel ; Angiographic evidence thrombus within target lesion ( ) ; Calcified target lesion ( ) , investigator 's opinion , successfully predilated ; Bifurcation disease involve side branch &gt; /= 2 mm diameter ; Prior stent within 5 mm target lesion ( ) ; Ostial target lesion ( ) ; Target lesion ( ) within coronary bypass graft ( e.g. , saphenous vein arterial graft ) ; Documented leave ventricular ejection fraction &lt; /= 25 % ; Impaired renal function ( creatinine &gt; 250 μmol/L &gt; 2.5 mg/dl ) time treatment ; Pretreatment device conventional balloon angioplasty ; Significant angulation target vessel , Investigator 's opinion , may preclude stent delivery deployment ; Subject previously treat brachytherapy ; Recipient heart transplant ; Subject life expectancy le 12 month ; Known allergy follow : aspirin , clopidogrel bisulfate ticlopidine , heparin , stainless steel , contrast agent ( manage medically ) , sirolimus manage medically ; Any significant medical condition , Investigator 's opinion , may interfere subject 's optimal participation study ; Currently participate investigational drug device study complete primary endpoint clinically interfere study endpoint ; In Investigator 's opinion , lesion suitable stenting ; Known bleed hypercoagulable disorder ; Known suspect active infection time study procedure ; Subject know pregnant , prisoner , mentally incompetent , and/or alcohol drug abuser ; Subject major surgical interventional procedure unrelated study within 30 day prior study planned surgical interventional procedure within 30 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>de novo native coronary lesion</keyword>
</DOC>